Breaking Finance News

A statement released earlier today by UBS Securities about Foundation Medicine (NASDAQ:FMI) raises the target price to $22.00

Yesterday Foundation Medicine (NASDAQ:FMI) traded -2.97% lower at $22.88. FMI’s 50-day average is $22.83 and its two hundred day average is $19.79. With the last stock price close up 15.72% from the 200-day moving average, compared to the S&P 500 which has decreased -0.01% over the same time. 116,792 shares of the stock were exchanged, down from an average trading volume of 198,827

In a report issued 9/21/2016 UBS Securities increased the stock price target of Foundation Medicine (NASDAQ:FMI) from $16.00 to $22.00 reporting a possible downside of -0.04%.

Recent Performance Chart

Foundation Medicine (NASDAQ:FMI)

Foundation Medicine has with a one year low of $13.34 and a one year high of $25.31 and has a market capitalization of $0.

Brief Synopsis On Foundation Medicine (NASDAQ:FMI)

Foundation Medicine, Inc. is a molecular information company. The Company sells products that are enabled by its molecular information platform to physicians and biopharmaceutical companies. The Company's segment is the business of delivering molecular information about cancer to its customers. Its products provide genomic information about each patient's individual cancer, enabling physicians to optimize treatments in clinical practice and biopharmaceutical companies to develop targeted oncology therapies. Its flagship clinical molecular information products, FoundationOne for solid tumors, and FoundationOne Heme for blood-based cancers or hematologic malignancies, including leukemia, lymphoma, myeloma and advanced sarcomas, are genomic profiles designed for use in the routine care of patients with cancer. Its other products include FoundationACT (Assay for Circulating Tumor deoxyribonucleic acid (DNA)), GeneKit, FoundationCORE, FoundationICE and the SmartTrials program.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with's FREE daily email newsletter.